Host impairments in patients with neoplastic diseases

  • Ben E. De Pauw
  • J. Peter Donnelly
  • Bart-Jan Kullberg
Part of the Cancer Treatment and Research book series (CTAR)


In the course of evolution nature has provided the normal human individual with an impressive and effective defense system against microbial enemies that eclipses even Star Wars, arguably the most advanced and ingenious defense program ever designed by human beings. On its own, the normal defense system recognizes foreign invaders, alerts the relevant protective mechanisms, launches counterattacks, ceases hostilities as soon as the job is done, and clears up the battlefield, causing only negligible collateral damage. An intact system offers protection against most microbial aggressors through a complex interrelationship of protecting surfaces, cells, and soluble factors.


Antimicrob Agent Alimentary Tract Neutropenic Patient Estramustine Phosphate Colonization Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Van der Meer JWM. Defects in host defense mechanisms. In: Rubin RH, Young LS, eds. Current Approach to Infection in the Compromised Host. New York: Plenum Medical, 1994, pp. 33–66.Google Scholar
  2. 2.
    Louria DB. Introduction and epidemiology. Am J Med 1984;76:414–420.PubMedCrossRefGoogle Scholar
  3. 3.
    Chandra RK. Nutrition, immunity and infection: Present knowledge and future directions. Lancet 1983;1:688–691.PubMedGoogle Scholar
  4. 4.
    Salimonu LS, Ojo-Amaize E, Williams AIO, et al. Depressed natural killer cell activity in children with protein calorie malnutrition. Clinl Immunol Immunopathol 1982;24:1–7.CrossRefGoogle Scholar
  5. 5.
    Sugarman B. Zinc and infection. Rev Infect Dis 1983;5:137–147.PubMedGoogle Scholar
  6. 6.
    Craddock PR, Yawata Y, van Santen L. Acquired phagoctye dysfunction: A complication of the hypophosphatemia of parenteral hyperalimentation. N Engl J Med 1974;290:1403–1407.PubMedCrossRefGoogle Scholar
  7. 7.
    Saltzman RL, Peterson PK. Immunodeficiency in the elderly. Rev Infect Dis 1987;9:1127–1139.PubMedGoogle Scholar
  8. 8.
    Meyers JD. Infection in bone marrow transplant recipients. Am J Med 1986;81(Suppl. lA):27–38.PubMedCrossRefGoogle Scholar
  9. 9.
    McGeer A, Feld R. Epidemiology of infection in immunocompromised oncological patients. Baillière’s Clin Infect Dis 1994;1:415–438.Google Scholar
  10. 10.
    Allen JC. The diabetic as a compromised host. In: Allen JC, ed. Infection and the Compromised Host: Clinical Correlations and Therapeutic Approaches, 2nd ed. Baltimore: Williams & Wilkins, 1981, pp. 229–270.Google Scholar
  11. 11.
    Rubin J, Yu VL. Malignant external otitis: Insights into pathogenesis, clinical manifestations, diagnosis and therapy. Am J Med 1988;139:557–563.Google Scholar
  12. 12.
    Cech P, Stalder H, Widmann JJ, et al. Leucocyte myeloperoxidase deficiency and diabetes mellitus associated with Candida albicans liver abscess. Am J Med 1979;66:149–153.PubMedCrossRefGoogle Scholar
  13. 13.
    Schwartz MN. Stress and the common cold. N Engl J Med 1991;325:654–656.CrossRefGoogle Scholar
  14. 14.
    Weitzman S, Aisenberg AC. Fulminant sepsis after the successful treatment of Hodgkin’s disease. Am J Med 1977;62:47–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination; an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980;303:549–552.PubMedCrossRefGoogle Scholar
  16. 16.
    Roth RR, James WD. Microbial ecology of the skin. Ann Rev Microbiol 1988;42:441–464.CrossRefGoogle Scholar
  17. 17.
    Kotilainen P, Nikoskelainen J, Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis 1990;161:41–44.PubMedGoogle Scholar
  18. 18.
    Weightman NC, Simpson EM, Speller DCE, Mott MG, Oakhill A. Bacteraemia related to indwelling central venous catheters: Prevention, diagnosis and treatment. Eur J Clin Microbiol Infect Dis 1988;7:125–129.PubMedCrossRefGoogle Scholar
  19. 19.
    Raad I.I, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992;15:197–210.PubMedGoogle Scholar
  20. 20.
    Hedin G, Hambraeus A. Multiply antibiotic-resistant Staphylococcus epidermidis in patients, staff and environment — a one-week survey in a bone marrow transplant unit. J Hosp Infect 1991;17:95–106.PubMedCrossRefGoogle Scholar
  21. 21.
    Groeger JS, Lucas AB, Thaler HT, Friedlanderklar H, Brown AE, Kiehn TE, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993;119:1168–1174.PubMedGoogle Scholar
  22. 22.
    Wood CA, Pepe R. Bacteremia in a patient with non-urinary tract infection due to Coryne-bacterium urealyticum. Clin Infect Dis 1994;19:367–368.PubMedGoogle Scholar
  23. 23.
    Castagnola E, Tasso L, Conte M, Nantron M, Barretta A, Giacchino R. Central venous catheter-related infection due to Comamonas acidovorans in a child with non-Hodgkin’s lymphoma. Clin Infect Dis 1994;19:559–560.PubMedGoogle Scholar
  24. 24.
    Alnor D, Frimodt-Moller N, Espersen F, Frederiksen W. Infections with the unusual human pathogens Agrobacterium species and Ochrobactrum anthropi. Clin Infect Dis 1994;18:914–920.PubMedGoogle Scholar
  25. 25.
    Weems JJ. Candida parapsilosis: Epidemiology, pathogenicity, clinical manifestations and antibiotic susceptibility. Clin Infect Dis 1992;14:756–766.PubMedGoogle Scholar
  26. 26.
    Lecciones JA, Lee JW, Navarro EE, Witesby FG, Marshall D, Steinberg SM, et al. Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes. Clin Infect Dis 1992;14:875–883.PubMedGoogle Scholar
  27. 27.
    Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-candida fungal infections following bone marrow transplantation. Medicine 1993;72:78–89.PubMedCrossRefGoogle Scholar
  28. 28.
    McNab PC, Tomasi TB. Host defense mechanisms at mucosal surfaces. Ann Rev Microbiol 1981;35:477–496.CrossRefGoogle Scholar
  29. 29.
    Kolbinson DA, Schubert MM, Fluornoy N, Truelove EL. Early oral changes following bone marrow transplantation. Oral Surg, Oral Med Oral Pathol 1988;66:130–138.CrossRefGoogle Scholar
  30. 30.
    Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B, et al. Oropharyn-geal mucositis complicating bone marrow transplantation: Prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989;4:89–95.PubMedGoogle Scholar
  31. 31.
    Donnelly JP, Muus P, Schattenberg A, Dewitte T, Horrevorts A, De Pauw BE. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant 1992;9:409–413.PubMedGoogle Scholar
  32. 32.
    Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil related stomatitis. Cancer 1993;72:2234–2238.PubMedCrossRefGoogle Scholar
  33. 33.
    Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: A review. Am J Med 1994;97:256–264.PubMedCrossRefGoogle Scholar
  34. 34.
    Donnelly JP, Dompeling EC, Meis JF, De Pauw BE. Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: Cytostatics are a more important risk factor than antibacterial prophylaxis. Clin Infect Dis 1995;20:469–470.PubMedGoogle Scholar
  35. 35.
    Beighton D, Carr AD, Oppenheim BA. Identification of viridans streptococci associated with bacteraemia in neutropenic cancer patients. J Med Microbiol 1994;40:202–204.PubMedGoogle Scholar
  36. 36.
    Lina B, Forey F, Troncy J, Greenland T. Fleurette J, Etienne J. Oral source of Staphylococcus epidermidis septicemia in a neutropenic patient. Eur J Clin Microbiol Infect Dis 1994;13:773–774.PubMedCrossRefGoogle Scholar
  37. 37.
    Jacobs JA, Pietersen HG, Stobberingh EE, Soeters PB. Bacteremia involving the “Streptococcus milled” group: Analysis of 19 cases. Clin Infect Dis 1994;19:704–713.PubMedGoogle Scholar
  38. 38.
    Ferretti GA, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. JADA 1987:114:461–67.PubMedGoogle Scholar
  39. 39.
    Meurman JH, Laine P, Murtomaa H, Lindqvist C, Torkko H, Teerenhovi L, et al. Effect of antiseptic mouthwashes on some clinical and microbiological findings in the mouths of lymphoma patients receiving cytostatic drugs. J Clin Periodont 1991;18:587–591.CrossRefGoogle Scholar
  40. 40.
    Bergmann OJ. Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloid leukaemia. Scand J Infect Dis 1991;23:355–366.PubMedCrossRefGoogle Scholar
  41. 41.
    Schuster MW. Granulocyte-macrophage colony-stimulating factor (GM-CSF) — what role in bone marrow transplantation. Infection 1992;20(Suppl. 2):S95–S99.PubMedCrossRefGoogle Scholar
  42. 42.
    Bronchud M. Can hematopoietic growth factors be used to improve the success of cytotoxic chemotherapy. Anti-Cancer Drugs 1993;4:127–139.PubMedCrossRefGoogle Scholar
  43. 43.
    De Witte T, Van Der Lely N, Muus P, Donnelly JP, Schattenberg T. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) accelerates bone marrow recovery after allogeneic T-cell depleted bone marrow transplantation. L’Ospedale Maggiore 1993;87:42–46.Google Scholar
  44. 44.
    McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nursing Forum 1993:20:1493–1502.Google Scholar
  45. 45.
    Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994;18:273–284.PubMedGoogle Scholar
  46. 46.
    Raemaekers J, De Witte T, Schattenberg A, Van Der Lely N. Prevention of leukaemic relapse after transplantation with lymphocyte-depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracyclines. Bone Marrow Transplant 1989:4:167–171.PubMedGoogle Scholar
  47. 47.
    Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988:108:30–35.PubMedGoogle Scholar
  48. 48.
    The EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 1990;26:569–574.CrossRefGoogle Scholar
  49. 49.
    The EORTC International Antimicrobial Therapy Cooperative Group and National Cancer Institute of Canada. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951–958.Google Scholar
  50. 50.
    Awada A, Van Der Auwera P, Meunier F, Daneau D, Klastersky J. Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis 1992:15:33–48.PubMedGoogle Scholar
  51. 51.
    Devaux Y, Archimbaud E, Guyotat D, Plotton C, Maupas J, Fleurette J, et al. Streptococcal bacteremia in neutropenic adult patients. Nouv Rev Fr Hematol 1992;34:191–195.PubMedGoogle Scholar
  52. 52.
    Menichetti F. Gram-positive infections in neutropenic patients —glycopeptide antibiotic choice. J Antimicrob Chemother 1992;29:461–462.PubMedCrossRefGoogle Scholar
  53. 53.
    Beattie G, Whelan J, Cassidy J, Milne L, Burns S. Leonard R. Herpes simplex virus, Candida albicans and mouth ulcers in neutropenic patients with non-haematological malignancy. Cancer Chemother Pharmacol 1989:25:75–76.PubMedCrossRefGoogle Scholar
  54. 54.
    Bergmann OJ. Oral infections in haematological patients —pathogenesis and clinical signifi-cance. Danish Med Bull 1992;39:15–29.PubMedGoogle Scholar
  55. 55.
    Van der Waaij D. The colonization resistance of the digestive tract of man and animals. In: Clinical and Experimental Gnotobiotics. New York: Gustav Fischer Verlag, 1979.Google Scholar
  56. 56.
    Schimpff SC. Infection prevention during profound granulocytopenia: New approaches to alimentary canal microbial suppression. Ann Intern Med 1980;93:358–361.PubMedGoogle Scholar
  57. 57.
    Young LS. Antimicrobial prophylaxis against infection in neutropenic patients. J Infect Dis 1983:147:611–614.PubMedGoogle Scholar
  58. 58.
    Van der Waaij D. The ecology of the human intestine and its consequences for overgrowth by pathogens such as Clostridium difficile. Ann Rev Microbiol 1989;43:69–87.Google Scholar
  59. 59.
    Vollaard EJ, Clasener HAL. Colonization resistance. Antimicrob Agents Chemother 1994;38:409–414.PubMedGoogle Scholar
  60. 60.
    Van der Waaij D. Effect of antibiotics on colonization resistance. In: Medical Microbiology. London: Academic Press, 1984, pp. 227–237.Google Scholar
  61. 61.
    Louie TJ, Chubb H, Bow EJ, Conly JM, Harding GKM, Rayner E, et al. Preservation of colonization resistance parameters during empiric therapy with aztreonam in febrile neutropenic patient. Rev Infect Dis 1985;7:S747–S761.PubMedGoogle Scholar
  62. 62.
    Meijer-Severs GJ, Van Santen E. Short-chain fatty acids and succinate in feces of healthy human volunteers and their correlation with anaerobic cultural counts. J Gastroenterol 1987:22:672–676.Google Scholar
  63. 63.
    Welling GW, Groen G. Inactivation of aztreonam by faecal supernatants of healthy volunteers as determined by HPLC. J Antimicrob Chemother 1989:24:805–810.PubMedCrossRefGoogle Scholar
  64. 64.
    Dietrich M, Rasche H, Rommel K, Hochapfel G. Antimicrobial therapy as a part of the decontamination procedures for patients with acute leukemia. Eur J Cancer 1973:9:443–447.PubMedGoogle Scholar
  65. 65.
    Bender JF, Schimpff SC, Young VM, Fortner CL, Brouillet MD, Love LJ, et al. Role of vancomycin as a component of oral nonabsorbable antibiotics for microbial suppression in leukemic patient. Antimicrob Agents Chemother 1979;15:455–460.PubMedGoogle Scholar
  66. 66.
    Pizzo PA, Robichaud KJ, Edwards BK, Schumaker C, Kramer BS, Johnson AJ. Oral antibiotic prophylaxis in patients with cancer: A double-blind randomized placebo-controlled trial. J Pediatr 1983;102:125–133.PubMedCrossRefGoogle Scholar
  67. 67.
    Walsh TJ, Schimpff SC. Prevention of infection among patients with cancer. Eur J Cancer Clinical Oncology 1983;19:1333–1344.CrossRefGoogle Scholar
  68. 68.
    Nord CE, Kager L, Heimdahl A. Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am J Med 1984;15:99–106.CrossRefGoogle Scholar
  69. 69.
    Jones PG, Bodey GP, Swabb EA, Rosenbaum B. Effect of aztreonam on throat and stool flora of cancer patients. Antimicrob Agents Chemother 1984;26:941–943.PubMedGoogle Scholar
  70. 70.
    Rozenberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: The effect on fecal flora. J Infect Dis 1985;152:104–107.PubMedGoogle Scholar
  71. 71.
    Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother 1989;24(Suppl. A):9–29.PubMedGoogle Scholar
  72. 72.
    Vollaard EJ, Clasener HAL, Janssen AJHM. The contribution of Escherichia coll to microbial colonization resistance. J Antimicrob Chemother 1990;26:411–418.PubMedCrossRefGoogle Scholar
  73. 73.
    Vollaard EJ, Clasener HAL, Janssen AJHM. Decontamination of the bowel by intravenous administration of pefioxacin. J Antimicrob Chemother 1990;26:847–852.PubMedCrossRefGoogle Scholar
  74. 74.
    Welling GW, Slootmakervandermeulen C, Jansen GJ. Inactivation of imipenem by faecal fractions from human volunteers and the effect of clavulanate and cilastatin. J Antimicrob Chemother 1993;31:617–619.PubMedCrossRefGoogle Scholar
  75. 75.
    Van der Waaij D, Hofstra H, Wiegersma N. Effect of β-lactam antibiotics on the resistance of the digestive tract of mice to colonization. J Infect Dis 1982;146:417–422.PubMedGoogle Scholar
  76. 76.
    Wiegersma N, Jansen G, Van Der Waaij D. Effect of twelve antimicrobial drugs on the colonization resistance of the digestive tract of mice and on endogenous potentially pathogenic bacteria. J Hygiene (Cambridge) 1982;88:221–230.Google Scholar
  77. 77.
    Clasener HA, Vollaard EJ, van Saene HK. Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation. Rev Infect Dis 1987;9:295–328.PubMedGoogle Scholar
  78. 78.
    Vollaard EJ, Clasener HAL, Van Griethuysen AJA, Janssen AJHM, Sanders-Reimers AHJ, Muller NF, et al. Influence of cefaclor, phenethicillin, co-trimoxazole and doxycycline on colonization resistance in healthy volunteers. J Antimicrob Chemother 1988;22:747–758.PubMedCrossRefGoogle Scholar
  79. 79.
    Van der Leur JJJPM, Thunnissen PLM, Clasener HAL, Muller NF, Dofferhoff ASM. Effects of imipenem, cefotaxime and cotrimoxazole on aerobic microbial colonization of the digestive tract. Scand J Infect Dis 1993;25:473–478.PubMedCrossRefGoogle Scholar
  80. 80.
    Vollaard EJ, Clasener HAL, Janssen AJHM. Co-trimoxazole impairs colonization resistance in healthy volunteers. J Antimicrob Chemother 1992;30:685–691.PubMedCrossRefGoogle Scholar
  81. 81.
    Meijer-Severs GJ, Joshi JH. The effect of new broad-spectrum antibiotics on faecal flora of cancer patients. J Antimicrob Chemother 1989;24:605–613.PubMedCrossRefGoogle Scholar
  82. 82.
    Chomarat M, Espinouse D. Lactobacillus rhamnosus septicemia in patients with prolonged aplasia receiving ceftazidime-vancomycin [letter]. Eur J Clin Microbiol Infect Dis 1991;10:44.PubMedCrossRefGoogle Scholar
  83. 83.
    Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. Engl J Med 1994;330:1240–1241.CrossRefGoogle Scholar
  84. 84.
    Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681–687.PubMedGoogle Scholar
  85. 85.
    Kern WV, Markus A, Andriof E. Bacteremia due to fluoroquinolone resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis 1994;13:161–165.PubMedCrossRefGoogle Scholar
  86. 86.
    Zinner SH, Calandra T, Meunier F, Gaya H, Viscoli C, Klastersky J, et al. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer —a trial of oral penicillin V or placebo combined with pefioxacin. JAMA 1994;272:1183–1189.CrossRefGoogle Scholar
  87. 87.
    Peters WG, Willemze R, Colly LP, Guiot HFL. Side effects of intermediate-and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute leukaemia and on-Hodgkins lymphoma. Neth J Med 1987;30:64–74.PubMedGoogle Scholar
  88. 88.
    Guiot HFL, Biemond J, Klasen E, Gratama JW, Kramps JA, Zwaan FE. Protein loss during acute graft-versus-host disease: Diagnostics and clinical significane. Eur J Haematol 1987;38:187–196.PubMedCrossRefGoogle Scholar
  89. 89.
    Callum JL, Brandwein JM, Sutcliffe SB, Scott JG, Keating A. Influence of total body irradiation on infections after autologous bone marrow transplantation. Bone Marrow Transplant 1991;8:245–251.PubMedGoogle Scholar
  90. 90.
    Johnson S, Driks MR, Tweten RK, Ballard J, Stevens DL, Anderson DJ, et al. Clinical courses of seven survivors of Clostridium septicum infection and their immunologic responses to a-toxin. Clin Infect Dis 1994;19:761–764.PubMedGoogle Scholar
  91. 91.
    Fegan C, Poynton JA, Whittaker JA. The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 1990;5:373–377.PubMedGoogle Scholar
  92. 92.
    Moody MR, Morris MJ, Young VM, Moye LA III, Schimpff SC, Wiernik PH. Effect of two cancer chemotherapeutic agents on the antibacterial activity of three antimicrobial agents. Antimicrob Agents Chemother 1978;14:737–742.PubMedGoogle Scholar
  93. 93.
    Jacobs JY, Michel J, Sacks T. Bactericidal effect of combinations of antimicrobial drugs and antineoplastic antibiotics against Staphylococcus aureus. Antimicrob Agents Chemother 1979;15:580–586.PubMedGoogle Scholar
  94. 94.
    Michel J, Jacobs JY, Sacks T. Bactericidal effect of combinations of antimicrobial drugs and antineoplastic antibiotics against gram-negative bacilli. Antimicrob Agents Chemother 1979;16:761–766.PubMedGoogle Scholar
  95. 95.
    Bodet CA III, Jorgensen JH, Drutz DJ. Antibacterial activities of antineoplastic agents. Antimicrob Agents Chemother 1985;28:437–439.PubMedGoogle Scholar
  96. 96.
    Neuman M. The antimicrobial activity of non-antibiotics —interactions with antibiotics. APMIS 1992;100(Suppl. 30):15–23.Google Scholar
  97. 97.
    Bergström P, Grankvist K, Henriksson R. Interaction between antibiotics and antineoplastic drugs on antibacterial activity in vitro: Estramustine phosphate sensitizes pneumococci to amikacin. Inte J Oncol 1994;4:43–439.Google Scholar
  98. 98.
    Van Cutsem JM, Thienpont D. Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy 1972;17:392–404.PubMedCrossRefGoogle Scholar
  99. 99.
    Ware AJ, Coller BS. Platelet morphology, biochemistry, and function. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ eds. Williams Hematology, (5th ed.) New York: McGraw-Hill, 1995, pp. 1161–1201.Google Scholar
  100. 100.
    Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. Eur J Cancer 1994;30A:430–437.PubMedCrossRefGoogle Scholar
  101. 101.
    Cronkite EP, Fliedner TM. Granulopoiesis. N Engl J Med 1964:270:1347–1352.PubMedCrossRefGoogle Scholar
  102. 102.
    Weller PF. The immunobiology of eosinophils. N Engl J Med 1991;324:1110–1114.PubMedCrossRefGoogle Scholar
  103. 103.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966:64:328–340.PubMedGoogle Scholar
  104. 104.
    Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975:135:715–719.PubMedCrossRefGoogle Scholar
  105. 105.
    EORTC International Antimicrobial Therapy Cooperative Group. Three antibiotic regimens in the treatment of infection in patients with cancer. J Infect Dis 1978;137:14–29.Google Scholar
  106. 106.
    Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine 1989;61:153–165.Google Scholar
  107. 107.
    DeGregorio MW, Lee WMF, Linker CA, Jacobs RA, Ries CA. Fungal infections in patients with acute leukemia. Am J Med 1982;73:543–548.PubMedCrossRefGoogle Scholar
  108. 108.
    Anaissie E, Bodey GP, Kantarjian H, et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989;11:369–378.PubMedGoogle Scholar
  109. 109.
    Bodey GP, Bueltman B, Duguid W, et al. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99–109.PubMedCrossRefGoogle Scholar
  110. 110.
    Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984:100:345–351.PubMedGoogle Scholar
  111. 111.
    Young RC, Corder MP, Haynes HA, et al. Delayed hypersensitivity in Hodgkin’s disease. Am J Med 1972;56:63–72.CrossRefGoogle Scholar
  112. 112.
    Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphatic leukemia. N Engl J Med 1991;325:81–86.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1998

Authors and Affiliations

  • Ben E. De Pauw
  • J. Peter Donnelly
  • Bart-Jan Kullberg

There are no affiliations available

Personalised recommendations